metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer HER 2 negative es-BC - HER2 negative - (neo)adjuvant (NA)
versus paclitaxel followed by doxorubicin plus cyclophosphamide
	pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
	I-SPY2, 2020 JAMA Oncol 2020 May Cancer 2014; 120:773 JAMA Oncol 2020 Sep 1;6(9):1355-1362. NCT01042379	RCT	es-BC - HER2 negative - (neo)adjuvant (NA)	pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide	paclitaxel followed by doxorubicin plus cyclophosphamide	Patients with ERBB2 (formerly HER2)-negative breast cance, women treated with neoadjuvant for early-stage breast cancer (stage II or III)	69 / 181	high	inconclusive	suggested 2.7-fold increase in pCR (PE)
mBC - HER 2 negative breast cancer HER 2 negative mBC - HER 2 negative
versus Standard of Care (SoC)
	durvalumab alone
	Saphir02 Breast-Immuno, 2021 Nat Med 2021; 27:250-255-. NCT02299999	RCT	metastatic/advanced - breast cancer (mBC)	durvalumab	chemotherapy	patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not progress after initial chemotherapy (maintenance chemotherapy).	131 / 68	some concern	inconclusive	inconclusive 40 % increase in progression or deaths (PFS) (PE) Maintenance chemotherapy was more effective than durvalumab in patients with hormone receptor-positive and Her2-negative disease.